Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will evaluate the efficacy and safety of metronomic oral paclitaxel combined with a PD-1 or PD-L1 inhibitor as maintenance therapy in patients with advanced lung cancer whose disease has not progressed after first-line chemoimmunotherapy. The study will include two independently analyzed cohorts. Cohort A will include patients with advanced squamous non-small cell lung cancer(sqNSCLC), and Cohort B will include patients with extensive-stage small cell lung cancer(ES-SCLC). All participants will receive oral paclitaxel three times weekly together with the same immune checkpoint inhibitor used during first-line induction therapy, whenever feasible. The primary outcome is progression-free survival. Other outcomes include tumor response, overall survival, adverse events, treatment tolerability, and quality of life. Approximately 107 participants will be enrolled across multiple study centers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzony płaskośródkowy rak płuca (kohora A) lub rozległy drobnokomórkowy rak płuca (kohora B)
- •Choroba zaawansowana, niemożliwa do operacyjnego leczenia
- •Ukończona pierwsza linia leczenia chemioterapią i lekami wspierającymi układ odpornościowy z dobrym efektem
- •Ostatnia dawka poprzedniego leczenia podana nie więcej niż 28 dni przed badaniem
- •Dobra ogólna kondycja zdolna do uczestniczenia w leczeniu
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Zadowalające funkcje szpiku kostnego i organów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Anhui Cancer Hospital
Hefei, China
Trial contact
Tian Tian, MD, PhD
Yueyin Pan, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.